Oesophageal Cancer Trial, Recruiting NCT06430346 Sponsor: H. Lee Moffitt Cancer Center and Research Institute Condition: Oesophageal Cancer
Back to Oesophageal Cancer

Oesophageal Cancer Trial, Recruiting

NCT06430346
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with esophageal cancer in the local or nearby area (confirmed by a tissue sample/biopsy)
  • Your doctor rates your general health and ability to carry out daily activities as reasonably good (on a standard scale used by doctors)
  • Your treatment plan includes chemotherapy and radiation therapy before surgery, followed by surgical removal of the tumor
  • You are able to read and speak English

Who may not be able to join:

  • You already regularly do strength/resistance exercises (such as weightlifting) at least twice a week, targeting all the main muscle groups in your body
  • You do not pass a standard exercise safety screening questionnaire called the PAR-Q (confirm with trial site)
  • You have an unstable heart or lung condition, or a heart condition that is causing you symptoms
  • You have had a recent bone fracture or sudden muscle or joint injury that would make it unsafe for you to do strength/resistance exercises
  • Your current pain level is 7 or higher on a scale of 0 to 10
  • You have a muscle disease or inflammatory joint/autoimmune condition that affects how well you can move or function physically (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Nathan Parker, PhD, Moffitt Cancer Center

Phone: 813-745-6849

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
21 May 2024
Est. completion
1 May 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Retention

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov